FDXF has now shed 17% in a month, and a fresh initiation from Citizens this week only underscores a widening paradox: the Street's conviction is building while the stock keeps sliding.
Citizens analyst Jeff Kauffman initiated coverage today with a Market Outperform rating and a $190 target — the most bullish entry yet in a coverage wave that has assembled quickly since the spin-off. Goldman Sachs kicked things off at Buy with $186. Jefferies holds the Street-high at $200. Raymond James, Evercore ISI, and Stephens & Co. are all Outperform or Overweight. The sceptics remain a small minority: Stifel, Truist, and BMO sit at Hold, with targets clustered between $150 and $160. The consensus mean now runs near $169, against a last close of $144.75. That implies roughly 17% upside — a gap that was 11% a week ago and 7% the week before. The discount to analyst targets is widening with each passing session, not compressing.
The borrow market offers no amplifying signal here. Availability is genuinely loose — roughly ten shares sit available to borrow for every one already lent out, and that ratio has actually expanded over the past week. Cost to borrow ticked up about 12% on the week to just over 0.51%, but the absolute level remains trivially low. Short interest trimmed about 4% on the week to roughly 3.36 million shares. There is no meaningful short-side pressure building; the selling is not coming from a crowded bear trade.
Options positioning is the one place where caution is legible. The put/call ratio is running at 1.38, well above its 20-day average of 1.08. That elevated ratio has been persistent across the past two weeks — it is not a single-day spike but a sustained tilt toward downside hedging. Notably, the PCR was near record lows in mid-June, right after the spin-off began trading, then rotated sharply higher as the stock rolled over through late June. Options traders have been paying for protection throughout the decline.
The ownership picture is worth noting given how new this stock is. FedEx Corporation retains just under 20% of shares, with BlackRock and State Street the next largest institutional holders at 3.1% and 1.6% respectively. Total institutional holder count stands at just 23 — a figure that reflects the stock's nascent public life more than any particular conviction signal. The entire institutional base is still forming. That thin ownership structure likely contributes to the price-action's vulnerability: there are few natural buyers with deep history in the name to step in during weakness.
The next scheduled catalyst is earnings on October 9. The only prior earnings print on record, from June 25, saw the stock fall 4.1% the next day and 6.0% over the following week. What to watch between now and then is whether the analyst target gap closes from the bottom up — meaning the stock recovers — or from the top down, with Hold-rated analysts cutting their numbers toward where shares are actually trading.
See the live data behind this article on ORTEX.
Open FDXF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
